A vs NBIX: Which Stock Is the Better Buy?
Agilent Technologies, Inc. and Neurocrine Biosciences, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — A vs NBIX, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Agilent Technologies, Inc. (A) | Neurocrine Biosciences, Inc. (NBIX) | |
|---|---|---|
| Market cap | $39.1B | $16.3B |
| Revenue (latest FY) | $6.95B | $2.86B |
| Net income (latest FY) | $1.30B | $478.60M |
| Revenue growth (5y CAGR) | 5.4% | 22.3% |
| Net margin | 18.8% | 16.7% |
| Return on equity | 19.3% | 14.7% |
| P/E ratio | 27.8 | 25.0 |
| Dividend yield | 0.7% | — |
| Profitable years (of last 10) | 10 | 8 |
| Positive free cash flow | Yes | Yes |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full A vs NBIX breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open A's full financials → Open NBIX's full financials →Frequently asked questions
Which is bigger, A or NBIX?
Agilent Technologies, Inc. is larger by market capitalization — $39.1B versus $16.3B.
Which grows faster, A or NBIX?
Over the last five fiscal years, Neurocrine Biosciences, Inc. grew revenue faster — 22.3%/yr versus 5.4%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.